Download PDF
Semin Respir Crit Care Med 2007; 28(3): 286-294
DOI: 10.1055/s-2007-981649
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Inflammation in Cystic Fibrosis-When and Why? Friend or Foe?

Caroline Elston1 , Duncan Geddes1
  • 1Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
Further Information

Publication History

Publication Date:
22 August 2007 (online)

    Permissions and Reprints

ABSTRACT

Pulmonary infection and an excessive neutrophil-driven inflammatory response are responsible for most of the morbidity and mortality associated with cystic fibrosis. Although inflammation is first and foremost a protective response to injury or infection it has the potential to cause considerable harm when it is excessive. Whereas most published reports emphasize the damaging effects of the chronic inflammatory response in cystic fibrosis, the beneficial effects are more difficult to quantify. Low levels of inflammation may assist in clearing infection, particularly early in the disease process, and surges of acute inflammation may be beneficial during exacerbations. Anti-inflammatory therapies are used to modify the inflammatory response but there is clearly a need to preserve the protective aspects of the inflammatory response because host defense and a fine balance exist between benefit and harm. The underlying processes involved in the inflammatory response are reviewed along with current and future anti-inflammatory therapies.

KEYWORDS

Cystic fibrosis - inflammation - host defense

REFERENCES

  • 1 Davis P B, Drumm M, Konstan M W. Cystic fibrosis.  Am J Respir Crit Care Med. 1996;  154 1229-1256
    PubMedGoogle Scholar
  • 2 Chmiel J F, Berger M, Konstan M W. The role of inflammation in the pathophysiology of CF lung disease.  Clin Rev Allergy Immunol. 2002;  23 5-27
    PubMedGoogle Scholar
  • 3 Kumar V, Cotran R S, Robbins S L. Robbins Basic Pathology. 7th ed. Philadelphia; Saunders 2003
    Google Scholar
  • 4 Bonfield T L, Panuska J R, Konstan M W et al.. Inflammatory cytokines in cystic fibrosis lungs.  Am J Respir Crit Care Med. 1995;  152(6 Pt 1) 2111-2118
    PubMedGoogle Scholar
  • 5 Khan T Z, Wagener J S, Bost T, Martinez J, Accurso F J, Riches D W. Early pulmonary inflammation in infants with cystic fibrosis.  Am J Respir Crit Care Med. 1995;  151 1075-1082
    PubMedGoogle Scholar
  • 6 Konstan M W, Walenga R W, Hilliard K A, Hilliard J B. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis.  Am Rev Respir Dis. 1993;  148(4 Pt 1) 896-901
    CrossrefPubMedGoogle Scholar
  • 7 Muhlebach M S, Stewart P W, Leigh M W, Noah T L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.  Am J Respir Crit Care Med. 1999;  160 186-191
    CrossrefPubMedGoogle Scholar
  • 8 Noah T L, Black H R, Cheng P W, Wood R E, Leigh M W. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.  J Infect Dis. 1997;  175 638-647
    PubMedGoogle Scholar
  • 9 Barnes P J, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.  N Engl J Med. 1997;  336 1066-1071
    CrossrefPubMedGoogle Scholar
  • 10 Bonfield T L, Konstan M W, Burfeind P, Panuska J R, Hilliard J B, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis.  Am J Respir Cell Mol Biol. 1995;  13 257-261
    PubMedGoogle Scholar
  • 11 Karp C L, Flick L M, Park K W et al.. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.  Nat Immunol. 2004;  5 388-392
    CrossrefPubMedGoogle Scholar
  • 12 Starosta V, Ratjen F, Rietschel E, Paul K, Griese M. Anti-inflammatory cytokines in cystic fibrosis lung disease.  Eur Respir J. 2006;  28 581-587
    CrossrefPubMedGoogle Scholar
  • 13 Gibson R L, Burns J L, Ramsey B W. Pathophysiology and management of pulmonary infections in cystic fibrosis.  Am J Respir Crit Care Med. 2003;  168 918-951
    CrossrefPubMedGoogle Scholar
  • 14 Taggart C C, Greene C M, Carroll T P, O'Neill S J, McElvaney N G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.  Am J Respir Crit Care Med. 2005;  171 1070-1076
    CrossrefPubMedGoogle Scholar
  • 15 Sagel S D, Sontag M K, Wagener J S, Kapsner R K, Osberg I, Accurso F J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis.  J Pediatr. 2002;  141 811-817
    CrossrefPubMedGoogle Scholar
  • 16 Matsui H, Grubb B R, Tarran R et al.. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.  Cell. 1998;  95 1005-1015
    CrossrefPubMedGoogle Scholar
  • 17 Smith J J, Travis S M, Greenberg E P, Welsh M J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.  Cell. 1996;  85 229-236
    CrossrefPubMedGoogle Scholar
  • 18 Moraes T J, Plumb J, Martin R et al.. Abnormalities in the pulmonary innate immune system in cystic fibrosis.  Am J Respir Cell Mol Biol. 2006;  34 364-374
    PubMedGoogle Scholar
  • 19 Pier G B. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections.  Proc Natl Acad Sci USA. 2000;  97 8822-8828
    CrossrefPubMedGoogle Scholar
  • 20 de Bentzmann S, Roger P, Dupuit F et al.. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells.  Infect Immun. 1996;  64 1582-1588
    PubMedGoogle Scholar
  • 21 Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface.  Proc Natl Acad Sci USA. 1995;  92 3019-3023
    PubMedGoogle Scholar
  • 22 Saiman L, Cacalano G, Gruenert D, Prince A. Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects.  Infect Immun. 1992;  60 2808-2814
    PubMedGoogle Scholar
  • 23 Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells.  J Clin Invest. 1993;  92 1875-1880
    PubMedGoogle Scholar
  • 24 DiMango E, Ratner A J, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.  J Clin Invest. 1998;  101 2598-2605
    PubMedGoogle Scholar
  • 25 Day B J, van Heeckeren A M, Min E, Velsor L W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary Pseudomonas infection.  Infect Immun. 2004;  72 2045-2051
    CrossrefPubMedGoogle Scholar
  • 26 Velsor L W, van Heeckeren A, Day B J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice.  Am J Physiol. 2001;  281 L31-L38
    PubMedGoogle Scholar
  • 27 Tirouvanziam R, Conrad C K, Bottiglieri T, Herzenberg L A, Moss R B, Herzenberg L A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.  Proc Natl Acad Sci USA. 2006;  103 4628-4633
    CrossrefPubMedGoogle Scholar
  • 28 Elphick H E, Demoncheaux E A, Ritson S, Higenbottam T W, Everard M L. Exhaled nitric oxide is reduced in infants with cystic fibrosis.  Thorax. 2001;  56 151-152
    CrossrefPubMedGoogle Scholar
  • 29 Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis.  Pediatr Pulmonol. 1997;  24 173-177
    CrossrefPubMedGoogle Scholar
  • 30 Kelley T J, Drumm M L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells.  J Clin Invest. 1998;  102 1200-1207
    CrossrefPubMedGoogle Scholar
  • 31 Chow C W, Landau L I, Taussig L M. Bronchial mucous glands in the newborn with cystic fibrosis.  Eur J Pediatr. 1982;  139 240-243
    CrossrefPubMedGoogle Scholar
  • 32 Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants.  Am J Pathol. 1982;  106 303-311
    PubMedGoogle Scholar
  • 33 Armstrong D S, Grimwood K, Carlin J B et al.. Lower airway inflammation in infants and young children with cystic fibrosis.  Am J Respir Crit Care Med. 1997;  156(4 Pt 1) 1197-1204
    PubMedGoogle Scholar
  • 34 Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.  Pediatr Pulmonol. 1995;  20 63-70
    CrossrefPubMedGoogle Scholar
  • 35 Rosenfeld M, Gibson R L, McNamara S et al.. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.  Pediatr Pulmonol. 2001;  32 356-366
    CrossrefPubMedGoogle Scholar
  • 36 Tirouvanziam R, de Bentzmann S, Hubeau C et al.. Inflammation and infection in naive human cystic fibrosis airway grafts.  Am J Respir Cell Mol Biol. 2000;  23 121-127
    PubMedGoogle Scholar
  • 37 Tabary O, Zahm J M, Hinnrasky J et al.. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro.  Am J Pathol. 1998;  153 921-930
    PubMedGoogle Scholar
  • 38 Bonfield T L, Konstan M W, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis.  J Allergy Clin Immunol. 1999;  104 72-78
    CrossrefPubMedGoogle Scholar
  • 39 Stecenko A A, King G, Torii K et al.. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells.  Inflammation. 2001;  25 145-155
    CrossrefPubMedGoogle Scholar
  • 40 Aldallal N, McNaughton E E, Manzel L J et al.. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis.  Am J Respir Crit Care Med. 2002;  166 1248-1256
    CrossrefPubMedGoogle Scholar
  • 41 Becker M N, Sauer M S, Muhlebach M S et al.. Cytokine secretion by cystic fibrosis airway epithelial cells.  Am J Respir Crit Care Med. 2004;  169 645-653
    CrossrefPubMedGoogle Scholar
  • 42 van Heeckeren A M, Schluchter M D, Xue W, Davis P B. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice.  Am J Respir Crit Care Med. 2006;  173 288-296
    CrossrefPubMedGoogle Scholar
  • 43 Armstrong D S, Hook S M, Jamsen K M et al.. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.  Pediatr Pulmonol. 2005;  40 500-510
    CrossrefPubMedGoogle Scholar
  • 44 Saadane A, Soltys J, Berger M. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation.  J Allergy Clin Immunol. 2006;  117 1163-1169
    CrossrefPubMedGoogle Scholar
  • 45 Gutierrez J P, Grimwood K, Armstrong D S et al.. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis.  Eur Respir J. 2001;  17 281-286
    CrossrefPubMedGoogle Scholar
  • 46 Meyer K C, Sharma A. Regional variability of lung inflammation in cystic fibrosis.  Am J Respir Crit Care Med. 1997;  156 1536-1540
    PubMedGoogle Scholar
  • 47 Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?.  Pediatr Pulmonol. 2005;  40 471-476
    CrossrefPubMedGoogle Scholar
  • 48 Armstrong D S, Grimwood K, Carzino R, Carlin J B, Olinsky A, Phelan P D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis.  BMJ. 1995;  310 1571-1572
    PubMedGoogle Scholar
  • 49 Colasurdo G N, Fullmer J J, Elidemir O, Atkins C, Khan A M, Stark J M. Respiratory syncytial virus infection in a murine model of cystic fibrosis.  J Med Virol. 2006;  78 651-658
    CrossrefPubMedGoogle Scholar
  • 50 Armstrong D, Grimwood K, Carlin J B et al.. Severe viral respiratory infections in infants with cystic fibrosis.  Pediatr Pulmonol. 1998;  26 371-379
    PubMedGoogle Scholar
  • 51 van Ewijk B E, van der Zalm M M, Wolfs T F, van der Ent C K. Viral respiratory infections in cystic fibrosis.  J Cyst Fibros. 2005;  4(Suppl 2) 31-36
    CrossrefPubMedGoogle Scholar
  • 52 Moss R B. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis.  Med Mycol. 2005;  43(Suppl 1) S203-S206
    CrossrefPubMedGoogle Scholar
  • 53 Burns J L, Gibson R L, McNamara S et al.. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.  J Infect Dis. 2001;  183 444-452
    CrossrefPubMedGoogle Scholar
  • 54 Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.  Pediatr Pulmonol. 1997;  23 330-335
    CrossrefPubMedGoogle Scholar
  • 55 Valerius N H, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.  Lancet. 1991;  338 725-726
    CrossrefPubMedGoogle Scholar
  • 56 Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.  Thorax. 1998;  53 732-737
    CrossrefPubMedGoogle Scholar
  • 57 Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.  Pediatr Pulmonol. 2002;  34 91-100
    CrossrefPubMedGoogle Scholar
  • 58 Nixon G M, Armstrong D S, Carzino R et al.. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.  J Pediatr. 2001;  138 699-704
    CrossrefPubMedGoogle Scholar
  • 59 Wiesemann H G, Steinkamp G, Ratjen F et al.. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.  Pediatr Pulmonol. 1998;  25 88-92
    CrossrefPubMedGoogle Scholar
  • 60 Wood D M, Smyth A R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.  Cochrane Database Syst Rev. 2006;  (1) , CD004197
    PubMedGoogle Scholar
  • 61 Hendry J, Elborn J S, Nixon L, Shale D J, Webb A K. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa .  Eur Respir J. 1999;  14 435-438
    PubMedGoogle Scholar
  • 62 Liou T G, Adler F R, Fitzsimmons S C, Cahill B C, Hibbs J R, Marshall B C. Predictive 5-year survivorship model of cystic fibrosis.  Am J Epidemiol. 2001;  153 345-352
    CrossrefPubMedGoogle Scholar
  • 63 Ordonez C L, Henig N R, Mayer-Hamblett N et al.. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.  Am J Respir Crit Care Med. 2003;  168 1471-1475
    CrossrefPubMedGoogle Scholar
  • 64 Dakin C J, Numa A H, Wang H, Morton J R, Vertzyas C C, Henry R L. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.  Am J Respir Crit Care Med. 2002;  165 904-910
    CrossrefPubMedGoogle Scholar
  • 65 Paul K, Rietschel E, Ballmann M et al.. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis.  Am J Respir Crit Care Med. 2004;  169 719-725
    CrossrefPubMedGoogle Scholar
  • 66 Birrer P, McElvaney N G, Rudeberg A et al.. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.  Am J Respir Crit Care Med. 1994;  150 207-213
    PubMedGoogle Scholar
  • 67 Ratjen F, Hartog C M, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha.  Thorax. 2002;  57 930-934
    CrossrefPubMedGoogle Scholar
  • 68 Brown R K, Kelly F J. Role of free radicals in the pathogenesis of cystic fibrosis.  Thorax. 1994;  49 738-742
    PubMedGoogle Scholar
  • 69 McGrath L T, Mallon P, Dowey L et al.. Oxidative stress during acute respiratory exacerbations in cystic fibrosis.  Thorax. 1999;  54 518-523
    PubMedGoogle Scholar
  • 70 Hays S R, Ferrando R E, Carter R, Wong H H, Woodruff P G. Structural changes to airway smooth muscle in cystic fibrosis.  Thorax. 2005;  60 226-228
    CrossrefPubMedGoogle Scholar
  • 71 Auerbach H S, Williams M, Kirkpatrick J A, Colten H R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.  Lancet. 1985;  2 686-688
    PubMedGoogle Scholar
  • 72 Eigen H, Rosenstein B J, FitzSimmons S, Schidlow D V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group.  J Pediatr. 1995;  126 515-523
    CrossrefPubMedGoogle Scholar
  • 73 Lai H C, FitzSimmons S C, Allen D B et al.. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.  N Engl J Med. 2000;  342 851-859
    CrossrefPubMedGoogle Scholar
  • 74 Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews (online). 2000 (2) CD001915
    Google Scholar
  • 75 Balfour-Lynn I M, Lees B, Hall P et al.. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.  Am J Respir Crit Care Med. 2006;  173 1356-1362
    CrossrefPubMedGoogle Scholar
  • 76 Konstan M W, Byard P J, Hoppel C L, Davis P B. Effect of high-dose ibuprofen in patients with cystic fibrosis.  N Engl J Med. 1995;  332 848-854
    CrossrefPubMedGoogle Scholar
  • 77 Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis.  Cochrane Database Syst Rev. 1999;  (2) , CD001505
    PubMedGoogle Scholar
  • 78 Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial.  Thorax. 2006;  61 895-902
    CrossrefPubMedGoogle Scholar
  • 79 Equi A, Balfour-Lynn I M, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.  Lancet. 2002;  360 978-984
    CrossrefPubMedGoogle Scholar
  • 80 Saiman L, Marshall B C, Mayer-Hamblett N et al.. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.  JAMA. 2003;  290 1749-1756
    CrossrefPubMedGoogle Scholar
  • 81 Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.  Thorax. 2002;  57 212-216
    CrossrefPubMedGoogle Scholar
  • 82 Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis.  Curr Opin Pulm Med. 2004;  10 515-523
    CrossrefPubMedGoogle Scholar
  • 83 Cigana C, Nicolis E, Pasetto M, Assael B M, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells.  Biochem Biophys Res Commun. 2006;  350 977-982
    CrossrefPubMedGoogle Scholar
  • 84 Schmitt-Grohe S, Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects.  Paediatr Drugs. 2005;  7 353-363
    PubMedGoogle Scholar
  • 85 Konstan M W, Doring G, Lands L et al,. on behalf of the investigators and coordinators of BI Trial 543.45. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease.  Paediatric Pulmonol. 2005;  125-126
    PubMedGoogle Scholar
  • 86 McElvaney N G, Hubbard R C, Birrer P et al.. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.  Lancet. 1991;  337 392-394
    CrossrefPubMedGoogle Scholar
  • 87 Martin S L, Downey D, Bilton D, Keogan M T, Edgar J, Elborn J S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.  Pediatr Pulmonol. 2006;  41 177-183
    CrossrefPubMedGoogle Scholar
  • 88 Yarden J, Radojkovic D, De Boeck K et al.. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype.  Thorax. 2005;  60 320-325
    CrossrefPubMedGoogle Scholar
  • 89 Hothersall E, McSharry C, Thomson N C. Potential therapeutic role for statins in respiratory disease.  Thorax. 2006;  61 729-734
    CrossrefPubMedGoogle Scholar
  • 90 Fessler M B, Young S K, Jeyaseelan S et al.. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense.  Am J Respir Crit Care Med. 2005;  171 606-615
    PubMedGoogle Scholar
  • 91 Kreiselmeier N E, Kraynack N C, Corey D A, Kelley T J. Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells.  Am J Physiol. 2003;  285 L1286-L1295
    PubMedGoogle Scholar
  • 92 Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis.  Am J Respir Crit Care Med. 2006;  174 208-212
    CrossrefPubMedGoogle Scholar
  • 93 Ballmann M, Junge S, von der Hardt H. Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis.  Respir Med. 2003;  97 498-500
    PubMedGoogle Scholar

Duncan GeddesM.D. F.R.C.P. 

Department of Respiratory Medicine, Royal Brompton Hospital

Sydney St., London SW3 6NP, UK

Email: d.geddes@rbht.nhs.uk

      >